CN119255803A - 用于治疗失眠的药物组合物和方法 - Google Patents

用于治疗失眠的药物组合物和方法 Download PDF

Info

Publication number
CN119255803A
CN119255803A CN202280096908.XA CN202280096908A CN119255803A CN 119255803 A CN119255803 A CN 119255803A CN 202280096908 A CN202280096908 A CN 202280096908A CN 119255803 A CN119255803 A CN 119255803A
Authority
CN
China
Prior art keywords
pharmaceutical composition
alprazolam
ebastine
amount
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280096908.XA
Other languages
English (en)
Chinese (zh)
Inventor
王建民
崔歌平
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CN119255803A publication Critical patent/CN119255803A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4515—Non condensed piperidines, e.g. piperocaine having a butyrophenone group in position 1, e.g. haloperidol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN202280096908.XA 2022-07-08 2022-07-08 用于治疗失眠的药物组合物和方法 Pending CN119255803A (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2022/036579 WO2024010592A1 (en) 2022-07-08 2022-07-08 Pharmaceutical compositions and methods for treating insomnia

Publications (1)

Publication Number Publication Date
CN119255803A true CN119255803A (zh) 2025-01-03

Family

ID=89453886

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280096908.XA Pending CN119255803A (zh) 2022-07-08 2022-07-08 用于治疗失眠的药物组合物和方法

Country Status (7)

Country Link
US (1) US20250205218A1 (https=)
EP (1) EP4551220A1 (https=)
JP (1) JP2025522146A (https=)
CN (1) CN119255803A (https=)
AU (1) AU2022468585A1 (https=)
CA (1) CA3261198A1 (https=)
WO (1) WO2024010592A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12370198B2 (en) 2022-07-08 2025-07-29 La Pharmatech Inc Pharmaceutical compositions and methods for treating psychiatric disorders

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10898493B2 (en) * 2019-04-12 2021-01-26 LA PharmaTech Inc. Pharmaceutical compositions and methods for psychiatric symptoms of patients with Alzheimer's disease
WO2021005189A1 (fr) * 2019-07-09 2021-01-14 Universite De Bretagne Occidentale (Ubo) Nouveaux composés inhibiteurs de la pfar

Also Published As

Publication number Publication date
EP4551220A1 (en) 2025-05-14
US20250205218A1 (en) 2025-06-26
WO2024010592A1 (en) 2024-01-11
AU2022468585A1 (en) 2025-02-20
CA3261198A1 (en) 2024-01-11
JP2025522146A (ja) 2025-07-10

Similar Documents

Publication Publication Date Title
US10898493B2 (en) Pharmaceutical compositions and methods for psychiatric symptoms of patients with Alzheimer's disease
JP5241228B2 (ja) 非ステロイド性抗炎症薬、鬱血除去薬および鎮静作用の少ない抗ヒスタミン薬を含む多層錠
KR101801864B1 (ko) 인플루엔자, 감기 및 염증의 치료에서 레보세티리진 및 몬테루카스트의 용도
US20090048288A1 (en) Method of treating stress-mediated depression
CN113924098A (zh) 治疗精神障碍、行为障碍、认知障碍的方法
US11690849B2 (en) Method of treating dementia
US20200323870A1 (en) Method of treating dementia
CN113939276A (zh) 用于治疗精神障碍、行为障碍、认知障碍的药物组合物和方法
US20210069209A1 (en) Novel pharmaceutical compositions and methods for menopause related anxiety and depression
WO2021242297A1 (en) Novel pharmaceutical compositions and methods for menopause related anxiety and depression
AU2014249530B2 (en) Use of levocetirizine and montelukast in the treatment of anaphylaxis
KR20150135339A (ko) 레보세티리진 및 몬테루카스트의 외상성 손상의 치료 용도
US20250205218A1 (en) Pharmaceutical compositions and methods for treating insomnia
US11744833B2 (en) Pharmaceutical compositions and methods for treatment of insomnia
JP2025518975A (ja) 精神疾患の治療のための新規医薬組成物及び方法
WO2023158424A1 (en) Novel pharmaceutical compositions and methods for treatment of insomnia
US11628174B1 (en) Pharmaceutical compositions and methods for treating insomnia
CN1268332C (zh) 用于治疗膀胱疾病的k－阿片受体激动剂
US12370198B2 (en) Pharmaceutical compositions and methods for treating psychiatric disorders
WO2015160249A2 (en) Use of enoximone in the treatment of atopic immune-related disorders, in pharmaceutical composition as well as in pharmaceutical preparation
JP4384435B2 (ja) くしゃみ抑制組成物
HK40119515A (zh) 用於治疗失眠症的新型药物组合物和方法
JP5106809B2 (ja) ラクトフェリンを含有する医薬組成物ならびに加工食品
JPWO2005063253A1 (ja) アレルギー症状治療用医薬組成物
WO2026080932A2 (en) Compounds, compositions, and methods of use thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination